Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAVA-1207 + interleukin-2
- Development stage
- Unknown
- Lead developer
- LAVA Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
LAVA-1207 + interleukin-2 is a **combination therapy** composed of LAVA-1207, a humanized bispecific antibody engineered to bind the Vδ2 chain of Vγ9Vδ2-T cells and the prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells, and low-dose interleukin-2 (IL-2), an immunomodulatory cytokine. LAVA-1207 acts as a γδ-T cell engager: by binding both Vγ9Vδ2-T cells and PSMA, it triggers targeted degranulation and cytolysis of PSMA-expressing prostate cancer cells. Low-dose IL-2 is included to support the expansion and activation of Vγ9Vδ2-T cells, enhancing the immune-mediated anti-tumor response. This combination is in clinical development for patients with metastatic castration-resistant prostate cancer (mCRPC) who are refractory to standard therapies[1][3][5][10].
- Other names
- LAVA-1207 + IL-2LAVA-1207 and low-dose interleukin-2LAVA1207 and low-dose interleukin-2LAVA 1207 and low-dose interleukin-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)PSMA (Prostate-specific membrane antigen)TRDV2 (T cell receptor delta variable 2)
Beyond the preview
Go deeper on LAVA-1207 + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAVA-1207 + interleukin-2.